U.S. markets open in 2 hours 12 minutes
  • S&P Futures

    4,512.50
    +1.25 (+0.03%)
     
  • Dow Futures

    35,333.00
    +10.00 (+0.03%)
     
  • Nasdaq Futures

    15,409.75
    +11.25 (+0.07%)
     
  • Russell 2000 Futures

    2,269.10
    -3.70 (-0.16%)
     
  • Crude Oil

    82.05
    -0.91 (-1.10%)
     
  • Gold

    1,782.10
    +11.60 (+0.66%)
     
  • Silver

    24.02
    +0.14 (+0.57%)
     
  • EUR/USD

    1.1641
    +0.0004 (+0.03%)
     
  • 10-Yr Bond

    1.6350
    0.0000 (0.00%)
     
  • Vix

    15.61
    -0.70 (-4.29%)
     
  • GBP/USD

    1.3758
    -0.0035 (-0.26%)
     
  • USD/JPY

    114.3860
    +0.0260 (+0.02%)
     
  • BTC-USD

    63,889.16
    +1,726.11 (+2.78%)
     
  • CMC Crypto 200

    1,480.87
    +17.51 (+1.20%)
     
  • FTSE 100

    7,222.56
    +5.03 (+0.07%)
     
  • Nikkei 225

    29,255.55
    +40.03 (+0.14%)
     

Why Cathie Wood Is Buying 2 Gene-Editing Stocks but Selling Another

·4 min read
Why Cathie Wood Is Buying 2 Gene-Editing Stocks but Selling Another
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Cathie Wood believes in the potential of gene editing. It's not surprising that Wood's ARK Genomic Revolution ETF (NYSEMKT: ARKG) and ARK Innovation ETF (NYSEMKT: ARKK) have invested heavily in several gene-editing stocks. The ARK Innovation ETF recently sold some of its shares of Editas Medicine (NASDAQ: EDIT).